Physician profile
Robert Burford Bashinsky
NPI 1730273186
$184.24
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $93.95 · 2020: $54.81 · 2021: $35.48.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $57.52 | 2019-2020 | |
| Pfizer INC. | $51.68 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $19.65 | 2019 | |
| Tris Pharma INC | $16.06 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.97 | 2019 | |
| Glaxosmithkline, LLC. | $12.37 | 2019 | |
| Merck Sharp & Dohme LLC | $10.99 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Bashinsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.